Xanax®
Alprazolam
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$300+
With Insurance
$10–25
Supplement Questions
How It Works
Alprazolam amplifies the brain's primary inhibitory system. It attaches to GABA-A receptors and acts like a turbocharger — GABA normally calms neural activity, and alprazolam makes every GABA signal dramatically more powerful.
Why the side effects happen
Benzodiazepines work across the entire brain wherever GABA-A receptors exist — which is everywhere. Sedation (alpha-1), anxiety relief (alpha-2), memory impairment (alpha-5 in hippocampus), and muscle relaxation (alpha-3 in spinal cord) all happen simultaneously. Tolerance develops because GABA-A receptors downregulate in response to constant enhancement — the brain reduces receptor numbers and sensitivity, requiring more drug for the same effect.
When Will I Feel It?
The fastest-acting commonly prescribed anxiolytic. Relief begins within 15–30 minutes. But this rapid onset is also why it is the most addictive benzodiazepine.
Anxiety relief begins. Physical symptoms (racing heart, tremor) calm first, then psychological worry.
Peak effect. Sedation at this point is common.
Wearing off. Rebound anxiety — anxiety that returns worse than before — is common at this stage. This drives redosing.
Tolerance develops to anxiolytic effect with regular use. Patients often need higher doses to achieve the same relief.
Adherence Note
Xanax has the shortest half-life of any commonly prescribed benzodiazepine (6–12 hours). The rapid offset produces rebound anxiety that feels like the underlying condition worsening — but is actually withdrawal from the drug itself. This cycle of relief → rebound → relief is the central mechanism of benzodiazepine dependence.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Sedation / drowsiness
41%Take at bedtime if possible; avoid driving or operating machinery
Memory impairment
30%Do not take before important events or tasks requiring recall
Coordination problems / ataxia
20%Especially dangerous in elderly — eliminate fall hazards at home
Rebound anxiety when stopping
>50%Never stop abruptly — requires a supervised taper; this is expected
Tolerance (reduced efficacy over time)
40%+Limit use to <4 weeks; dependence risk increases sharply beyond this
Sexual dysfunction
10%Discuss with prescriber; often improves with dose reduction
Serious Adverse Effects
- • Physical dependence and addiction (40–60% of patients using >6 weeks)
- • Withdrawal seizures if stopped abruptly — can be life-threatening
- • Respiratory depression when combined with opioids or alcohol
- • Long-term cognitive impairment with chronic use
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Physical dependence and addiction (40–60% of patients using >6 weeks)
- Withdrawal seizures if stopped abruptly — can be life-threatening
- Respiratory depression when combined with opioids or alcohol
- Long-term cognitive impairment with chronic use
- Seizures — call 911 immediately
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Category D. Neonatal benzodiazepine withdrawal syndrome. Risk of cleft palate in first trimester.
Excreted in breast milk. Infant sedation and feeding problems reported.
Anxiety, irritability, and panic-like symptoms are very common during perimenopause due to estrogen and progesterone fluctuations. These are frequently treated with benzodiazepines when the underlying cause is hormonal. Benzodiazepines carry significant dependence and cognitive risks — especially for women over 40. Ask your doctor about evaluating hormones before starting an anti-anxiety medication during the menopause transition.
No approved pediatric dosing. Off-label use in adolescents is discouraged; dependence risk is higher in developing brains.
Beers Criteria: high-risk medication in elderly. 3–4× increased hip fracture risk, cognitive impairment, falls.
Dose reduce in severe renal impairment; monitor for excessive sedation.
Hepatic impairment significantly raises alprazolam levels. Start at 25–50% of normal dose.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Anxiety Without Dependency: Evidence-Based Alternatives
CBT produces equal or better outcomes to benzodiazepines at 12 months — without addiction or withdrawal
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Cognitive Behavioral Therapy (CBT)
12–16 sessions
Equal efficacy to benzos at 12 months; lower relapse; no dependence
Aerobic exercise
30 min, 3–5x/week
Reduces anxiety symptoms 48%; comparable to low-dose benzodiazepine
Magnesium glycinate
300–400mg at night
RCT: significant reduction in mild-to-moderate anxiety
Diaphragmatic breathing / 4-7-8 technique
10 min twice daily
Activates parasympathetic nervous system; reduces cortisol measurably
Ashwagandha (KSM-66)
300–600mg/day
RCT: 56% reduction in anxiety scores vs 30% placebo
How It Compares
Xanax has the highest abuse potential of all commonly prescribed benzodiazepines due to its rapid onset and short half-life. The combination produces the most reinforcing reward-withdrawal cycle.
Strengths
- Fastest onset of any oral benzodiazepine
- Effective for acute panic attacks
- Short duration (some users prefer this)
Weaknesses
- Shortest half-life = worst discontinuation syndrome of any oral benzo
- Highest abuse potential
- Rebound anxiety between doses drives dose escalation
- No approved indication beyond anxiety — not FDA approved for long-term use
Clinically Preferred Alternatives
Global Prescribing & Pricing
US prescribes benzodiazepines at 5× the rate of most European countries
United States
$30–80 (generic)/mo
1 in 8 adults prescribed a benzodiazepine annually — highest globally
No mandatory therapy prerequisite; any physician can prescribe; refills readily available
Usually covered
United Kingdom
~$5–15/mo
Lower prescribing — strict NICE 2–4 week limit
NICE guidelines mandate maximum 2–4 weeks prescribing; therapy first for anxiety disorders
Covered by NHS with restrictions
France
~$5–12/mo
Still higher than northern Europe but 2.5× lower than US
Psychotherapy must be offered alongside; maximum 12-week prescription; tight renewal controls
Covered by Sécurité Sociale with restrictions
Germany
~$8–18/mo
Significantly lower — psychotherapy pathway well-funded
GKV subsidizes CBT wait times; strict 2–4 week acute use guidelines; no long-term prescribing
Covered by GKV with restrictions
Australia
~$15–30/mo
Lower prescribing; PBS limits quantities
PBS restricts repeats; quantity limits; prescriber must document acute indication
PBS limited quantities
The UK's 2–4 week maximum prescribing rule for benzodiazepines — combined with NHS-funded CBT — means the vast majority of anxiety patients receive effective therapy rather than a dependency-forming pill. The US has no equivalent national guideline, producing the world's highest benzo prescribing rate.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
Virtually all pivotal Xanax trials were funded by Upjohn (now Pfizer). The manufacturer shaped dosing guidelines, minimized addiction data, and omitted long-term dependence findings from early publications. Benzodiazepine research has a long history of industry-controlled outcomes.
Declared Conflicts of Interest
Upjohn conducted and controlled the Cross-National Panic Study. Researchers who later raised dependence concerns were marginalized. Post-marketing studies revealing 40%+ dependence rates at 6+ weeks received minimal academic attention relative to efficacy data.
Key Efficacy Results
70–80% short-term symptom reduction; 40–60% develop physical dependence after 6 weeks; efficacy wanes with tolerance
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Alprazolam. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Alprazolam in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| NIMH Anxiety Disorders Study | NCT00000393 | |
| Cross-National Panic Study | PMID:3524107 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Abrupt alprazolam discontinuation can cause life-threatening seizures. Benzodiazepine withdrawal is one of the two withdrawal syndromes (with alcohol) that can be directly fatal. Tapering must be slow and medically supervised.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Published protocols describe switching to an equivalent dose of a longer-acting benzodiazepine (diazepam) as a first step — this smooths the stopping process significantly
- ·Research supports reducing by no more than 5–10% of total dose every 1–2 weeks — published evidence consistently shows slower reductions are safer
- ·For high-dose or long-term users, published tapering literature documents processes taking 6–24 months
- ·Research supports reducing by no more than 10% of the CURRENT dose (not original dose) per step
- ·The Ashton Manual protocol is widely cited in clinical literature as the reference approach for benzodiazepine stopping
- ·Clinical guidelines recommend monitoring for withdrawal symptoms and pausing dose reductions if symptoms become severe
Warning Symptoms — Contact Your Doctor If You Experience:
- Seizures — call 911 immediately
- Tremors or uncontrollable shaking
- Extreme anxiety or panic disproportionate to your normal level
- Hallucinations or psychosis
- Rapid heartbeat with sweating
- Insomnia that is severe and worsening
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Can we start with therapy or a non-addictive medication instead?
- 2.What is the plan for stopping this medication — and what is the maximum duration you recommend?
- 3.Am I at risk of dependence given my history?
- 4.Are SSRIs or buspirone appropriate for my situation instead?
- 5.What happens to my body if I miss a dose or stop suddenly?
Lab Tests to Request
- Liver function (before long-term use)
- Anxiety scale (GAD-7) to track response
- Depression screen (benzodiazepines can unmask depression)
- Fall risk assessment (elderly)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Xanax®
- What is Xanax® used for?
- Xanax® (Alprazolam) is a Benzodiazepine manufactured by Pfizer/Generic. FDA-approved indications include: Generalized anxiety disorder; Panic disorder; Short-term anxiety relief.
- What are the common side effects of Xanax®?
- Common side effects of Xanax® include: Sedation / drowsiness (41%); Memory impairment (30%); Coordination problems / ataxia (20%); Rebound anxiety when stopping (>50%); Tolerance (reduced efficacy over time) (40%+).
- How much does Xanax® cost?
- Xanax® list price is approximately $300+. With insurance it typically costs $10–25; without insurance approximately $30–80.
- Who funded the clinical trials for Xanax®?
- Virtually all pivotal Xanax trials were funded by Upjohn (now Pfizer). The manufacturer shaped dosing guidelines, minimized addiction data, and omitted long-term dependence findings from early publications. Benzodiazepine research has a long history of industry-controlled outcomes.
- How strong is the clinical evidence for Xanax®?
- Key studies: Cross-National Collaborative Panic Study (1992), multiple Upjohn-funded trials 1980s–90s. 70–80% short-term symptom reduction; 40–60% develop physical dependence after 6 weeks; efficacy wanes with tolerance Potential conflicts of interest: Upjohn conducted and controlled the Cross-National Panic Study. Researchers who later raised dependence concerns were marginalized. Post-marketing studies revealing 40%+ dependence rates at 6+ weeks r.
- Are there non-drug alternatives to Xanax®?
- CBT produces equal or better outcomes to benzodiazepines at 12 months — without addiction or withdrawal See the Alternatives tab for full details.
Get notified when we update Xanax®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.